HPS-190 - Real-world evaluation of administration-site reactions and patient preference regarding subcutaneous trastuzumab in Chinese patients with early breast cancer

• At: Copenhagen (Denmark) (2025)
• Type: Poster
• Poster code: HPS-190
• By: ZHU, Zhixiang (Cancer Hospital, Chinese Academy Of Medical Sciences, China)
• Co-author(s): Mr Zhixiang Zhu (Cancer Hospital, Chinese Academy Of Medical Sciences, Beijing, China)
  Ms Cuicui Wang (Cancer Hospital, Chinese Academy Of Medical Sciences, Beijing, China)
  Professor Yuanyuan Dai (Cancer Hospital, Chinese Academy Of Medical Sciences, Beijing, China)
  Professor Guo Li (Cancer Hospital, Chinese Academy Of Medical Sciences, Beijing, China)
  
• Abstract:

  Introduction
  Trastuzumab, a humanised monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2), significantly improves clinical outcomes for HER2-positive breast cancer patients. Originally developed as intravenous (IV) infusion, trastuzumab (T-IV) requires prolonged administration time, additional nursing resources, and..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login